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THE ROLE OF TRAF6 PHOSPHORYLATION IN 
Src/TRAF6-MEDIATED IKK, JNK, Akt 
ACTIVATION AND TUMORIGENESIS 
 
Yun Seong Jeong, Ph.D. 
Supervisory Professor: Hui-Kuan Lin, Ph.D. 
  
        TRAF6 E3 ligase regulates numerous essential biological processes such as innate 
immune response, cell survival and osteoclast differentiation. Upon activation, it 
mediates activation of IKK/NF-κB and JNK signaling in response to engagement of toll-
like receptor 4 (TLR4), interleukin-1 receptor (IL-1R), and receptor activator of NF-κB 
(RANK) to their cognate ligands, including lipopolysaccharide (LPS), IL-1, and RANK 
ligand (RANKL). Recently, TRAF6 has also been shown to be involved in Akt signaling 
activation upon activation of insulin-like growth factor-1 receptor (IGF-1R), in turn 
orchestrating cell survival and tumorigenesis. Therefore, TRAF6 is a key player for the 
activation of IKK, JNK and Akt by diverse receptor signaling. Although TRAF6 activity 
is induced by these receptors, the mechanism by which TRAF6 is activated under these 
stimulating conditions remains largely unclear. 
         Here, we show that TRAF6 Y473 phosphorylation is commonly induced and serves 
as an essential mode for TRAF6 activation by multiple signaling stimuli including IGF-1, 
IL-1, LPS, and RANKL. We identify Src tyrosine kinase as a direct kinase for TRAF6 
and a mediator of TRAF6 Y473 phosphorylation. Notably, we find that Src or Traf6 
deficiency impairs IKK, Akt, and JNK activation, which can be rescued by 
phosphomimetic TRAF6, but not by phosphorylation-dead TRAF6 mutant. 
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Mechanistically, we show that TRAF6 phosphorylation is imperative for TRAF6 
dimerization/oligomerization and its binding to E2 enzyme, UBC13. Significantly, we 
find that TRAF6 phosphorylation is critical for TRAF6-mediated cancer progression and 
represents a biomarker for poor survival outcome. Our study therefore resolves the long-
standing puzzle of achievement of TRAF6 activation and elucidates TRAF6 
phosphorylation as a central mode for Src/TRAF6-mediated downstream kinase 
activation and tumorigenesis  
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INTRODUCTION 
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1-1. Ubiquitination pathways 
        Protein ubiquitination is involved in regulating numerous essential biological 
processes [1,2,3]. Initially, protein ubiquitination is considered as a posttranslational 
modification for protein degradation through 26S proteasome pathway [4]. Recently, it 
has also been found that protein ubiquitination has non-proteolytic functions such as 
receptor endocytosis, DNA damage repair, protein trafficking, and regulation of kinase 
signaling activation (Figure 1-1) [1,5,6]. 
        Ubiquitin is a highly conserved 76 amino acid protein [7]. Ubiquitination is a three -
step enzymatic process that covalently attaches the ubiquitin(s) to lysine (K) residues of 
target proteins[7]. There are three classes of enzymes, E1 (ubiquitin activating enzyme), 
E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase), which participate in the 
ubiquitination process.  Initially, ubiquitin is activated by E1 enzyme in an ATP-
dependent manner and the activated ubiquitin is then transferred to E2 enzyme. Next, the 
E3 ubiquitin ligase recognizes its specific target proteins, and then the activated ubiquitin 
is transferred from E2 to target proteins (Figure 1-1)[8]. During the ubiquitination 
process E2 enzyme determines the formation of ubiquitin chains.  Ubiquitin has seven 
lysine residues, K6, K11, K27, K29, K33, K48 and K63, which are all involved in the 
formation of ubiquitination chains [9].  So far, K48-linked and K63-linked ubiquitination 
have been well studied. The K48-linked ubiquitination chain is recognized by the 26S 
proteasome for protein degradation [7]. Although it is known that most E2s trigger the 
K48-linked ubiquitination, resulting in protein degradation through 26S proteasome, the 
roles of ubiquitination are not restricted to protein degradation. Mono and 
multiubiquitination formation play roles in endocytosis, apoptosis, regulation of 
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transcription, and DNA repair. The K63-linked ubiquitination chain has non-proteolytic 
functions such as receptor endocytosis, DNA damage repair, protein trafficking and 
kinase signaling activation [1,2,3,10,11] (Figure 1-1). Although other types of ubiquitin-
linked chains are also observed, the exact physiological relevance of these linkages is still 
unclear [8,12,13]. Interestingly, it has been recently reported that TRAF6 is implicated in 
pathogenesis of neurodegenerative diseases including Huntington diseases and 
Parkinson’s disease by promoting atypical ubiquitination of misfolded mutant DJ-1, α-
synuclein and N-HTT, proteins related to Parkinson’s disease and Huntington disease 
pathogenesis.  Instead of the typical K63–linked ubiquitination of target proteins, TRAF6 
was shown to promote K6-, K27-, and K29-linked ubiquitination of misfolded mutant 
DJ-1, α-synuclein and N-HTT resulting in aggregation of mutant DJ-1, α-synuclein and 
N-HTT in neurodegenerative disease [14,15].   
          Although most E2 enzymes facilitate the K48-linked ubiquitination, one of the E2 
enzymes, UBC13, mostly mediates the K63-linked ubiquitination with its cofactor 
UEV1A [9]. The E3 ubiquitin ligase family members fall into two groups, which 
comprise of homologous to the E6-AP carboxyl terminus (HECT) domain group and a 
really interesting new gene (RING) domain group [1]. Whereas most E3 ligases 
recognize substrates for K48-linked ubiquitination, it is known that TRAF6, HectH9 
(homologous to E6-AP carboxyl terminus homologous protein 9), c-IAP1/2 (cellular 
inhibitor of apoptosis protein 1/2), and RNF8 (ring finger protein 8) recognize target 
protein for K63-linked ubiquitination [1,16,17,18,19].  
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Figure1-1.Ubiquitination regulates protein degradation or activation.  
Ubiquitination is a three step enzyme reaction. Ubiquitin is activated by the E1, 
ubiquitin-activating enzyme, and is then transferred to an E2, ubiquitin-conjugating 
enzyme. The ubiquitin will be finally transferred from the E2 to a lysine residue of target 
protein by E3 ubiquitin ligase. Ubiquitination regulates the fate of proteins. The K48–
linked ubiquitination of target protein leads to degradation through the 26S proteasome 
pathway. Whereas the K63-linked ubiquitination regulates signaling activation involved 
in various biological functions including DNA damage, receptor endocytosis and protein 
trafficking.  
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1-2. The tumor necrosis factor receptor (TNF-R)-associated factors (TRAFs) 
        TRAFs were first identified as cytoplasmic adaptor proteins that are directly 
associated with numerous TNF-R superfamily [20,21,22]. There are seven TRAF family 
members identified (Figure 1-2) in mammals. Among TRAFs, TRAF6 also mediates 
signaling other than TNF-R superfamily. For example, TRAF6 is participated in IL-1R, 
IL-18R, TLR and Akt signaling [22,23].  
        The TRAF proteins consist of N-terminal RING-finger, which facilitates E3 ligase 
functions, a zinc-finger motif and C-terminal TRAF-C domain, which mediate TRAF 
oligomerization and interactions with upstream regulators including receptors and 
downstream effector proteins [21,22,24] (Figure 1-2). Among TRAFs, TRAF2, TRAF3, 
TRAF5 and TRAF6 have been demonstrated to have E3 ligase activity, which mediate 
K63-linked ubiquitination [22,25,26].  
        The TRAFs have distinct expression patterns. TRAF2, 3 and 6 are expressed 
ubiquitously. However, TRAF1, 4, and 5 are expressed more distinctly. TRAF1 is 
expressed in tonsil, spleen, lung and testis [27], TRAF4 is expressed during 
embryogenesis and in neural tissues [28], and TRAF5 expression has been observed in 
spleen, lung, and thymus [29,30]. 
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Figure 1-2. Characteristics of TRAF protein domain. 
The TRAF family member consists of seven proteins. Except TRAF1, TRAFs have a 
RING domain which facilitates E3 ligase function and zinc-finger motif. TRAF-C 
domain is highly conserved among the TRAFs and mediate TRAF oligomerization and 
associations with upstream regulators including receptors and downstream effector 
proteins. TRAF7 has seven WD40 domains instead of TRAF-C. TRAF7 interacts with 
MEKK3 using WD40 domain. 
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1-3. TRAF proteins in activating NF-κB and AP-1 transcription factors   
        Association of TRAFs to TNF-R typically leads to activation of NF-κB and AP-1 
transcription factors.  NF-κB is a dimeric transcription factor consisting of c-Rel, RelA 
(p65), RelB, p50, and p52. NF- κB has a highly conserved REL-homology domain (RHD) 
that is required for DNA binding, dimerization, nuclear translocation and interaction with 
IκB protein [31,32,33]. NF-κB activation pathways can be divided by either canonical or 
the non-canonical pathway depending on involving IκB degradation or p100 processing 
[33,34]. In the canonical pathway, stimulation with TNF-R, IL-1R and TLRs induce 
activation of IκB kinase (IKK) complex consisting of IKKα, IKK, and NEMO (IKK). 
The active IKK complex phosphorylates IκB, resulting in its degradation. The NF-κB is 
then released from IκB and translocates into the nucleus to regulate target genes that 
control cytokines, adhesion molecules, transcription factors, and survival factors. In the 
non-canonical pathway, stimulation with BAFF, Lymphotoxin-(LT) and CD40 ligand 
induce activation of the protein kinase NIK and IKKα, leading to p100 phosphorylation, 
ubiquitination, and production of p52. The p52 and RelB then translocate into the nucleus 
to regulate target gene expression.  
        AP-1 transcription factor is a dimeric complex, which consists of Jun, Fos or 
activating transcription factor proteins including ATF2, ATF3, or B-ATF.  It is known 
that a stress-related MAP kinase, Jun N-terminal kinase (JNK) activates c-Jun to regulate 
target genes that control cell cycle, cell survival, and apoptosis, metalloproteinases, and 
nuclear hormone receptors [35]. TRAF proteins activate JNK by activating upstream 
MAP3Ks such as TGF- activating kinase 1(TAK1)[36], ASK1[37,38], MEKK1[39], 
and MAP4K GCK[40].  
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1-4. Regulation of TRAF proteins in signaling 
        Ubiquitination is a key regulatory mechanism of TRAFs in signaling.  As mentioned 
in 1-1, K63-linked ubiquitination of TRAFs mediates non-degradation functions such as 
promoting protein interaction and signal transduction. For example, in IL-17R signaling, 
Act1 catalyzes K63-linked ubiquitination of TRAF6 leading to NF-κB activation [41], 
while Pellino3 ubiquitinates TRAF6 at Lys124 leading to limited ability of TRAF6 to 
induce IRF7 ubiquitination. This results in inhibiting production of type I interferon (IFN) 
in TLR3 signaling pathway [42].  In contrast to K63-linked ubiquitination, K48-linked 
ubiquitination of TRAF leads to degradation of TRAFs through 26S proteasome pathway. 
For example, cIAP1/2, Triad3A, AWP1, SOCS2, Siva-1, Numbl and CHIP have been 
shown as K48-linked E3 ligases of TRAFs [43] (Table 1-1). 
        Deubiquitinases also regulate TRAFs (Table 1-2). A NF-κB target gene, CYLD has 
negative impacts on NF-κB and JNK activation by removing K63-linked ubiquitin chains 
of TRAF2 and TRAF6 [44,45].  Up-regulation of DUBA expression is observed in TLR 
and IL-1R stimulated cells [46,47,48]. DUBA removes the K63-linked ubiquitin chains 
of TRAF3, leading to TBK1-IKKε separation from TRAF3 and reducing production of 
Type I IFN in TLRs [46,47,48]. Another interesting example of deubiquinase, A20, 
contains both ubiquitinating and deubiquitinating activities. A20 negatively regulates NF- 
κB activation in TNF-R and TLR signaling. A20 is also an NF- κB target gene and 
removes K63-linked ubiquitin chains of TRAF6 to inhibit NF-κB activation. Interestingly, 
A20 is able to block E3 ligase activities of TRAF2, TRAF6, cIAP1 by catalyzing K48-
linked ubiquitination and degradation of E2 enzymes, UBC13 and UBCH5 [25,46,49]. In 
addition, A20 is able to target TRAF2 for lysosomal degradation. 
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        In addition to ubiquitination and deubiquitination, it is also reported that 
phosphorylation and glutathionylation regulate TRAFs in signaling.  PKN1-mediated 
TRAF1 S146 phosphorylation negatively regulates TNF-R2-dependent NF-κB and JNK 
signaling activation in HeLa cells and T cells [50,51]. Phosphorylation of TRAF2 by 
PKCζ, IKKε, PKCδ, or PKCε promotes K63-linked ubiquitination of TRAF2 and NF-κB 
activation in TNF-R signaling and transformed cells [52,53,54,55]. IKKα-mediated 
TRAF4 S426 phosphorylation upon NOD2 (nucleotide binding-oligomerization domain 2) 
activation inhibits NF-κB activation, cytokine production, and antibacterial activity in 
macrophage [56]. Interestingly, it is reported that under normal conditions TRAF6 is S-
glutathionylated. Upon IL-1 stimulation, glutathionylation of TRAF6 is removed by 
glutaredoxin-1 and this deglutathionylation is required for TRAF6 auto-ubiquitination 
and TRAF6-mediated NF-κB activation [57].   
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Table 1-1. E3 ligases that promote ubiquitination of TRAFs     
E3 ligases Targets Receptor signaling Ubiquitin-linkage 
    
Act1 TRAF6 (Lys124) IL-17R K63 
 TRAF5 IL-17R K63 
 
cIAP1/2 TRAF3 and TRAF6 RIG-1 K63 
 TRAF2 TNF-R2 K48 
 TRAF2 M-CSFR K48 
 TRAF2 and TRAF3 CD40 and TLR4 K48 
 TRAF3 and TRAF6 RIG-I K48 
 
Pellino3 TRAF6 (Lys124) TLR3 K63 
 
Triad3A TRAF3 RIG-I K48 
 
AWP1 TRAF2 TNF-R1/2 K48 
 
SOCS2 TRAF6 AhR K48 
 
Siva-1 TRAF2 TCR K48 
 
Numbl TRAF6 and TRAF5 IL-1R K48 
 
CHIP TRAF2 Cancer cell invasion K48 
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Table 1-2. Deubiquiting enzymes of TRAFs 
DUBs TRAFs  Signaling Reference 
    
A20 TRAF6 TLR2, TLR4 [25,46,49] 
 
CYLD TRAF2,TRAF6 CD40,XEDAR,EDAR,RANK 
IL-1R, TNF-α 
 
[44,45] 
DUBA (OUTD5) TRAF3 IL-1R,TLR9,TLR3,TLR4, 
TLR7, RIG-I, MDA-5 
 
[46,47,48] 
MCPIP1 TRAF2,TRAF3,TRAF6 IL-1R, TLR4 [58] 
 
OTUB1  TRAF3,TRAF6 RIG-I [59] 
 
OTUB2 TRAF3,TRAF6 RIG-I [59] 
 
USP2a TRAF2 TNFR1 [60] 
 
  TRAF6 IL-1R and RIG-1 [61] 
 
USP4 TRAF2,TRAF6 TNF-α [62] 
 
 TRAF6 IL-1R,TLR4  
 
USP20 TRAF6 IL-1R [63] 
 
USP25 TRAF5,TRAF6 IL-17R [64] 
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1-5. TRAF6 regulates various signaling pathways 
        TRAF6 is a unique TRAF family member involved in TLR-4/IL-1- and TNFR-
mediated NF-B and AP-1 activation. Upon activation with cognate ligands of TLR4/IL-
1R such as lipopolysaccharide (LPS) or IL-1, MyD88, IRAK1 and IRAK4 are associated 
with the cognate receptor. After IRAK4 phosphorylates IRAK1, phosphorylated IRAK1 
then interacts with TRAF6, leading to activated E3 ligase function and K63-linked 
ubiquitination. Even though this model is recently challenged, these K63-linked ubiquitin 
chains of TRAF6 have been reported to serve as a scaffold to recruit to TAK1 and IKK 
complexes [1,65]. TAK1 phosphorylate IKK complex and MAP kinase, which result in 
activation of NF-κB and AP-1[1,65,66] (Figure 1-3).  
        In addition to LPS and IL-1, TRAF6 also mediates CD40 ligand (CD40L), receptor 
activator of NF-κB ligand (RANKL)-induced NF-κB activation [67]. TRAF6 is also 
participated in TGF-β-mediated activation of JNK and p38, but not canonical activation 
of Smad signaling pathway [68,69,70,71,72]. Whereas the kinase activity of type I 
serine/threonine kinase TGF-β receptor (TRI) is required for activation of Smad 
signaling pathway, TRAF6 activates and regulates TAK1 activation. Upon TGF-β 
stimulation, TRAF6 is recruited to TRI leading to TRAF6 autoubiquitination and 
activation. This enhances TRAF6 mediated K63-linked ubiquitination and activation of 
TAK1, resulting in phosphorylation and activation of p38 and JNK to regulate cell 
apoptosis in a receptor independent manner [68,69,70,71,72]. Interestingly, in cancer 
cells, it is reported that TRAF6 is also involved in TGF-β-mediated cancer cell invasion 
[73]. Upon stimulation with TGF-β, TRAF6 promotes K63-linked ubiquitination of TRI 
resulting in TRI cleavage by TNF-α converting enzyme (TACE) in a PKCζ-dependent 
13 
 
manner [73]. The intracellular domain of TRI then interacts with the p300 to regulate 
genes controlling invasion of cancer cells. In addition, TRAF6 also mediates inhibitory 
impact   of LPS or IL-1 on TGF--mediated signaling pathway.  Co-stimulation with 
TGF- and LPS or IL-1 induces TRAF6 ubiquitination and association with 
phosphorylated TRIII. This releases TRIII from TRII/TRI complex, leading to 
inhibition of Smad2/3 activation [74]. These suggest that TRAF6 may have multiple 
functions in TGF-β-receptor -mediated signaling.  
        Recently, TRAF6 has also been shown to be involved in Akt signaling activation 
upon activation of insulin-like growth factor-1 receptor (IGF-1R), in turn orchestrating 
cell survival and tumorigenesis [23]. We showed that TRAF6 is an E3 ligase for Akt and 
induces its K63-linked ubiquitination, leading to Akt membrane recruitment, 
phosphorylation, and activation upon stimulation by growth factor IGF-1[23].  Therefore, 
TRAF6 is a key player for the activation of IKK, JNK and Akt by diverse receptor 
signaling.  
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Figure 1-3. TRAF6-mediated activation of NF-κB and AP-1 in the TLR4 and IL-1R 
Ligand-stimulated TLR4 and IL-1R recruit the adaptor MyD88, which in turn recruits 
IRAK1 and IRAK4. IRAK4 is activated and phosphorylates IRAK1. Phosphorylated 
IRAK1 then associates with TRAF6. This association leads to TRAF6 activation and then 
TRAF6 promotes the synthesis of K63-linked polyubiquitin chains. These chains serve as 
a scaffold to recruit both TAK1 and IKK complexes. TAK1 phosphorylate IKK complex 
and MAP kinase, which result in activation of NF-κB and AP-1. 
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1-6. Src family tyrosine kinases and their structures 
       The Src tyrosine family kinases (SFKs) are implicated in regulating multiple signal 
transduction pathways that regulate cell differentiation, migration, invasion, proliferation, 
and cell survival [75]. They are non-receptor type tyrosine kinases consisting of 9 kinase 
members, Src, Fyn, Yes, Frk, Blk, Fgr, Hck, Lck and Lyn. Their distribution and 
expression patterns are distinct in normal tissues. For examples, Src, Fyn, Yes, and Frk 
are ubiquitously found, whereas Blk, Fgr, Hck, Lck, and Lyn are expressed in specific 
cells [76,77] (Table 1-3). 
        SFKs share well conserved distinct protein domains including Src homology 4 
(SH4) domain, Src homology 3(SH3) domain, Src homology 2 (SH2) domain, kinase 
domain (SH1), and a short C-terminal tail (Figure.1-4).  The N-terminal SH4 domain 
facilitates myristoylation and palmitoylation. It is well reported that myristoylation and 
palmitoylation regulate membrane recruitment, kinase activity and stability [77,78,79]. 
SH3 and SH2 domains play important roles in binding adaptor proteins and 
phosphotyrosine residue on itself. The SH1 Kinase domain regulates enzymatic activities 
and substrate binding. A C-terminal domain contains negative regulatory site that 
interacts with the SH2 domain (Figure 1-4).   
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Table1-3.Known functions and expression pattern of Src family kinases  
SFKs Expression Functions Reference 
    
Src Ubiquitous Cell proliferation,adhesion,migration, 
chemotaxis,phagocytosis and survival 
[80] 
 
 
Fyn Ubiquitous T-cell inhibition and Rac and stress kinase 
activation 
 
 
[81] 
Lyn Platelet, granulocyte 
Monocyte, macrophage, 
B cell 
 
Netrophil recruitment 
Inhibition of platelet aggregation 
 
[82] 
Lck T cell, B cell Regulation of signaling and B-1 cell fate [83] 
 
Hck  Granulocyte,monocyte,
macrophage 
Inhibition of Hck and Fgr kinase activity [84] 
 
 
Fgr  Granulocyte,monocyte,
macrophage 
Inhibition of Hck and Fgr kinase activity 
Inhibition of β2integrin receptor and Syk 
kinase signaling 
 
[84,85] 
 
Blk Granulocyte,monocyte,
macrophage, B cell 
Control of b cell proliferation [86] 
 
     
Frk Ubiquitous Unclear  
    
 
Yes Ubiquitous LTB4-mediated degranulation [87] 
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Figure1-4. The structure of Src kinase. 
The Src is consists of an N-terminal myrisotylation or palmitoylation sequence attached 
to the SH4 domain followed by SH3 and SH2 domains, a kinase domain (SH1) which 
contains positive regulatory site Y416, and C-terminal regulatory domain which contains 
Y527. 
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1-7. The regulation of SFK activity 
      The regulation of SFK activity is achieved through both intramolecular and 
intermolecular interactions. SFK kinase activity is majorly regulated by conformational 
changes by phosphorylation and dephosphorylation of its own two major tyrosine 
residues, Tyr 527 and Tyr 416.  Particularly, Tyr 527 phosphorylation is critical 
regulatory site for Src activity regulation. SFK activity is negatively regulated when Tyr 
527 is phosphorylated, interacts with the SH2 domain, and at the same time, the SH3 
domain interacts with polyproline motifs. In this closed conformation, ATP and substrate 
binding are prevented. Contrarily, dephosphorylation of Tyr 527 leads to conformational 
change from closed configuration to open configuration by disrupting the interaction of 
the SH2 or SH3 domain with C-terminal tail and proline motifis. This allows the SFK 
kinase to access substrate proteins and lead to autophosphorylation of Tyr 416, which is 
critical for full kinase activity [79,88,89,90] (Figure 1-5). This inhibitory phosphorylation 
of Tyr 527 in SFK can also be achieved by two other tyrosine kinases, C-terminal Src 
kinase (Csk)[91] and Csk homology kinase [92].  
        Interestingly, different regulatory phosphorylation site has been reported recently. It 
has been shown that human epidermal growth factor receptor2 (HER2) or platelet-
derived growth factor receptor (PDGFR)-mediated phosphorylation of Src Y212 inhibit 
interaction with C-terminal regulatory sequence, leading to Src activation[93].  
        It is also known that protein phosphatases are involved in regulating SFK activity by 
dephosphorylating Tyr 527 in SFKs.  Multiple protein tyrosine phosphatases (PTPs) 
including T-cell protein tyrosine phosphatase (TCPTP), the SH2 domain-containing 
protein tyrosine phosphatases 1 and 2 (SHP1 and SHP2), PTP1B, PTPα, PTPε, PTPκ, 
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and receptor-PTPα (R-PTPα) dephosphorylate Tyr 527 and induce active formation of 
SFKs[94,95].    
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Figure 1-5. Activation of Src tyrosine kinase. 
Phosphorylation of Y527 is a key negative regulatory event associated with closed 
conformation. SFKs are activated when extracellular ligands such as growth factors bind 
to cognate receptors. Phosphorylation of Y416 is a key positive molecular event for full 
kinase function. 
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CHAPTER 2 
MATERIALS  
AND  
METHODS 
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2-1. Cell culture  
        Wild-type and Traf6
-/-
 MEFs were prepared as described previously [23].  Src
-/-
 MEF 
cells were kind gift from Dr. Zhimin Lu (MD Anderson cancer center, Houston, TX). 
HEK 293, HEK 293T, PC-3, Hep3B, MDA-MB-231 and MEF cells were grown in 
DMEM containing 10% FBS, and Raw264.7 cells were grown in RPMI medium 
containing 10% FBS. 
2-2. Reagents  
        Recombinant active Src and RANKL were purchased from Millipore.  Src inhibitor, 
PP2, was purchased from Sigma. IGF-1 was purchased from Calbiochem and Sigma. 
LPS, murine and human IL-1β was purchased from PeproTech. BMH cross-linker was 
obtained from Thermo Scientific. Glutathione-agarose beads were purchased from 
Invitrogen. 8-μm polyethylene terephthalate membrane inserts were purchased from 
Becton-Dickinson. Matrigel was purchased from BD sciences. 
 
2-3. Plasmids 
        To create pWZL-HA-TRAF6 construct, the Traf6 gene was amplified from pCR3-
Flag-TRAF6 by PCR and then subcloned into pWZL-Hygro vector with a HA-tagged 
sequence. TRAF6 mutant constructs ,pCR3.1-Flag-TRAF6 Y56F, pCR3.1-Flag-TRAF6 
Y56E, pCR3.1-Flag-TRAF6 Y68F, pCR3.1-Flag-TRAF6 Y68E, pCR3.1-Flag-TRAF6 
Y217F, pCR3.1-Flag-TRAF6 Y217E, pCR3.1-Flag-TRAF6 Y231F, pCR3.1-Flag-
TRAF6 Y231E, pCR3.1-Flag-TRAF6 Y326F, pCR3.1-Flag-TRAF6 Y326E, pCR3.1-
Flag-TRAF6 Y353F pCR3.1-Flag-TRAF6 Y353E, pCR3.1-Flag-TRAF6 Y406F, 
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pCR3.1-Flag-TRAF6 Y406E, pCR3.1-Flag-TRAF6 Y418F, pCR3.1-Flag-TRAF6 Y418E, 
pCR3.1-Flag-TRAF6 Y473F, pCR3.1-Flag-TRAF6 Y473E, pMX-Flag-TRAF6 Y473F, 
pMX-Flag-TRAF6 Y473E, pMX-Flag-TRAF6 Y473D, pGEX-4X1-TRAF6 Y473F, 
pWZL-HA-TRAF6 Y473E, pWZL-HA-TRAF6 Y473F were generated by standard 
mutagenesis protocol using a site-directed mutagenesis kit (Stratagene). Src Y527F and 
Src K295R plasmids were gifts from Dr. Dihua Yu (MD Anderson cancer center, 
Houston, TX). 
2-4.  Immunoprecipitation (IP) and Immunoblottng (IB).  
        IP and IB were carried out as described previously [23,83]. For IP experiment, PBS 
washed cells were harvested, and lysed with E1A lysis buffer 250mM NaCl, 50mM 
HEPES, (pH7.5), 0.1% NP40, 5 mM EDTA, 5 mM NaV, 1 mM NaF , 1 mM PMSF, 
protease inhibitor cocktail (Roche). 1-2 mg Protein lysates were then incubated with 
specific antibody at 4ºC for 2hrs to overnight. Protein A/G beads (Santa Cruz) were 
added and incubated at 4ºC for 1-3 hrs to pull down antibody-protein complex.  
Following antibodies were used for IP and IB experiments: anti-phospho-tyrosine (IB: 
1:1000; Cell Signaling), anti-phospho-tyrosine (IB: 1:500; Santa Cruz), anti-TRAF6 (IP: 
1:100; IB: 1: 10000; LifeSpan Biosciences), anti-TRAF6 (IP: 1:200; IB: 10000; 
Calbiochem), anti-TRAF6 (IP: 1:100; IB: 1:1000; Santa Cruz), anti-phospho (Y473)-
TRAF6 (IB: 1000; New England Peptide), anti-Src (IB: 1:1000, Cell signaling), anti-
phospho (Y416)-Src (IB: 1: 1000; Cell signaling), anti-phospho (Y527)-Src (IB: 1:1000; 
Cell signaling), anti-ubiquitin (IB: 1:1000; Santa Cruz), anti-panAkt (IB: 1:5000; Cell 
Signaling), anti-phospho (T308)-Akt (IB: 1: 1000; Cell Signaling), anti-phospho (S473)-
Akt (IB: 1:1000; Cell Signaling), anti-phospho-Foxo1 (T24)/Foxo3a (T32) (IB: 1:1000; 
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Cell Signaling), anti-Foxo3a (IB: 1:1000; Millipore), anti-phospho (S176/180)-IKKα/β 
(IB: 1: 1000; Cell Signaling), anti-phospho (S32/36)-IκBα (IB: 1: 1000; Cell Signaling), 
anti-phospho (T187)-TAK-1(IB: 1: 1000; Cell Signaling), anti-phospho (T183/Y185)-
JNK(IB: 1:1000; Cell Signaling),  anti-Flag (M2, IP: 1:200; IB: 1: 3000, Sigma), anti-HA 
(IB: 1: 10000, Covance, Upstate),  anti-β-actin (IB: 1:10000;Sigma ), and anti-UBC13 
(IB: 1:1000; Invitrogen). 
2-5. In Vitro Src kinase assay.  
        Purified recombinant GST-TRAF6 and GST-TRAF6 Y473F proteins were used for 
substrates of Src kinase. BL-21 bacterial cells were transformed with pGEX-4X-1-
TRAF6 and pGEX-4X-1-TRAF6 Y473F plasmids. GST-TRAF6 and GST-TRAF6 
Y473F proteins were then purified by using glutathione-agarose beads according to the 
manufacturer’s manual. Purified GST-TRAF6 and GST-TRAF6 Y473F proteins were 
incubated with recombinant active Src protein for 15min at room temperature in the 
1kinase buffer (25mM Tris-HCl pH7.5, 5mM β-glycerophosphate, 2mM dithiothreitol, 
0.1mM Na3VO4, 10mM MgCl2, and 0.5mM ATP). Reactions were terminated by boiling 
in 2 SDS loading buffer. IB analysis was then carried out with the indicated antibodies. 
2-6. In Vivo Ubiquitination Assay.  
        In vivo ubiquitination assays were carried out as previously described [23,83]. HEK 
293T cells were co-transfected with the indicated plasmids for 24-48hr and PBS washed 
cells were harvested, and lysed in the denaturing buffer (6M guanidine-HCl, 0.1M 
Na2HPO4/NaH2PO4, 10 mM imidazole).  The cell extracts were then incubated with 
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nickel beads for 3hr at room temperature. IB analysis was then carried out with the 
indicated antibodies. 
2-7. Generation of phospho-TRAF6 (Y473) antibody.  
        The phospho-TRAF6 (Y473) peptide (CRNPKGFGY
P
VTFMH) was synthesized 
and injected into the rabbit three times. Double affinity purification was then carried out 
according to the manufacturer’s standard procedures (New England Peptide). For 
immunoblotting, the phospho-TRAF6 (Y473) antibody was blocking with the TRAF6 
non-phospho-peptide (CRNPKGFGYVTFMH) [5 (peptide): 1 (antibody); w/w] at 4˚C 
overnight before performing IB experiment.  
 
2-8. Protein cross-linking.  
        To evaluate TRAF6 oligomerization, protein cross-linking was carried out according 
to the manufacturer’s standard procedure. In brief, cytokine or growth factor stimulated 
cells were washed with ice cold PBS and then lysed and incubated with 0.2mM BMH at 
room temperature for 1hr. The reaction was terminated by adding and boiling with 2x 
SDS loading buffer, followed by IB analysis with the indicated antibody. 
 2-9. Cell growth assay.  
        For the cell growth assay, 5103 cells were seeded in 12 well plates, collected, and 
stained with trypan blue on the indicated days. Viable cells were counted under the 
microscope.  
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2-10. Cell migration and invasion assays. 
        The cell migration assay was carried out in 24-well transwell plate with 8-μm 
polyethylene terephthalate membrane filter inserts (Falcon cell culture insert; Becton-
Dickinson). 10
5
 PC-3, Hep3B, or MDA-MB-231 cells with Mock, TRAF6 wild-type, 
Y473D, and Y473F stable overexpression were plated in the upper chambers with serum 
free DMEM. DMEM media containing 10% FBS was put in the bottom chamber. After 
18 hr incubation for PC-3 and Hep3B or 5hr incubation for MDA-MB-231, cells in the 
top of the filter were wiped out and migrating cells on the lower filter were fixed with 4% 
formaldehyde for 20min, and stained with Crystal violet for 20min. Three to five random 
fields were then counted. The cell invasion assay was carried out similarly to cell 
migration assay, but using matrigel-coated filter inserts (Matrigel: serum free DMEM, 
1:5).   
2-11. Viral infection and in vivo tumorigenesis assay  
        Viral infection and in vivo tumorigenesis assay were performed as described 
previously [23]. Phoenix packaging cells were transfected with retroviral plasmid PMX, 
PMX-TRAF6, PMX-TRAF6 Y473D, and PMX-TRAF6 Y473F for were 2 days, and the 
virus-containing media were collected, filtered and used to infect target cells. For 
lentiviral shRNA production, TRAF6-lentiviral shRNA (5’-
GCCACGGGAAATATGTAATATCT-3’) and GFP control shRNA(5’-
gcaagctgaccctgaagttc-3’) were used. TRAF6 or GFP control shRNA plasmids along with 
packaging plasmids (delta VPR8.9) and envelop plasmid (VSV-G) were co-transfected 
into HEK 293T cells using Lipofectamine 2000 reagent according to the manufacturer’s 
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standard manual for 2days.  Filtered virus particles were then used to infect 293 cells. All 
infected cells were selected in media with 2 μg/ml puromycin for 1 week. For in vivo 
tumorigenesis assay, Mock, TRAF6 WT, TRAF6 Y473D, TRAF6 Y473F stably 
overexpressing PC-3 cells (4105) were mixed with matrigel (1:1) and subcutaneously 
injected into 6-week-old female nude mice. The tumor size was then measured every 
week with a caliper, and tumor volume was calculated by the following formula: LW2 
0.52.  L is the longest diameter and W is the shortest diameter. 
2-12. Patients and human materials 
        The institutional review board of Chi-Mei Medical Center had approved 
procurement of formalin-fixed tissues and acquisition of clinical information for this 
study (IRB10210004). Immunoexpression was assessed on 212 consecutively treated 
primary breast carcinomas that had undergone modified radical mastectomy between 
1997 and 2002. No adjuvant chemotherapy was given in these patients. Pathological 
staging was assigned based on the 7
th
 edition of American Joint Committee on Cancer 
(AJCC) system.  
2-13. Immunohistochemistry and scoring  
        The procedures of immunohistochemical studies were performed as previously 
described [96]. In brief, sections were cut onto an adhesive-coated glass slides at 3-µm 
thickness. For staining in human samples, the slides were incubated with primary 
antibodies targeting pSrc
Tyr416
 (Cell Signaling, polyclonal, 1:50), pTRAF6 
Tyr473
 (New 
England Peptide, 1:50), pAkt
Ser473
 (Cell Signaling, clone D9E, 1:25), and pIkkα/β (Cell 
Signaling, clone 16A6, 1:20), respectively. Primary antibodies were detected using the 
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ChemMate
 
DAKO EnVision kit (DAKO, K5001).
 
The slides were incubated with the 
secondary antibody for 30 minutes and developed with 3, 3-diaminobenzidine for 5 
minutes.
 
Incubation without the primary antibody was used as a negative control. 
Immunoexpression was scored using a multiheaded microscope to reach a consensus for 
each case on the H-score, defined by using the following equation: H-score = ΣPi (i + 1), 
where i is the intensity of the stained tumor cells (0 to 4 +), and Pi is the percentage of 
stained tumor cells for each intensity. 
2-14. Statistical analysis 
        Statistical analyses were performed using the SPSS 14 software package. The 
Kruskal-Wallis H test and Mann-Whitney U test were used to assess the differential 
expression level of pSrc
Tyr416
, pTRAF6
 Tyr473
, pAkt
Ser473, and pIkkα/β expression in 
relation to important clinicopathologic variables. The Pearson’s correlation coefficient 
was used to clarify the association between pSrc
Tyr416
, pTRAF6
 Tyr473
, pAkt
Ser473
, and 
pIkkα/β expression levels. The endpoint analyzed was disease-specific (DSS) and distal 
metastasis-free survivals (MeFS), which were calculated from the starting date of 
surgery to the date disease-related death or metastatic events. The median period of 
follow-up was 103.7 months (range, 6 to 144). Univariate survival analysis was 
performed using the Cox proportional hazards model. Survival curves were plotted using 
the Kaplan-Meier method, and log-rank tests were performed to evaluate prognostic 
differences between groups for categorical variables. A multivariate model was 
performed using Cox proportional hazards regression, including parameters with 
univariate p<0.05. Since primary tumor status (pT) and nodal status (pN) are component 
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factors of tumor stage, only stage was enrolled into multivariate analysis. For all 
analyses, two-sided tests of significance were used with p=< 0.05 considered significant. 
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CHAPTER 3 
The Role of TRAF6 Phosphorylation in 
Src/TRAF6-mediated IKK, JNK, Akt 
Activation and Tumorigenesis 
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A.RATIONALE 
       TRAF6 is a critical E3 ubiquitin ligase that regulates diverse biological processes, 
such as innate immunity, osteoclast differentiation, and cell survival. Upon activation, it 
mediates activation of IKK/NF-κB and JNK signaling activation in response to 
engagement of toll-like receptor 4 (TLR4), interleukin-1 receptor (IL-1R), and receptor 
activator of NF-κB (RANK) to their cognate ligands, including lipopolysaccharide (LPS), 
IL-1, and RANK ligand (RANKL) [1,66,97,98,99]. Recently, TRAF6 has also been 
shown to be involved in Akt signaling activation upon activation of insulin-like growth 
factor-1 receptor (IGF-1R), in turn orchestrating cell survival and tumorigenesis [23]. We 
showed that TRAF6 is an E3 ligase for Akt and induces its K63-linked ubiquitination, 
leading to Akt membrane recruitment, phosphorylation, and activation upon stimulation 
by growth factor IGF-1[23].  Therefore, TRAF6 is a key player for the activation of IKK, 
JNK and Akt by diverse receptor signaling. Although TRAF6 activity is induced by these 
receptors, the mechanism by which TRAF6 is activated under these stimulating 
conditions remains largely unclear. Understanding how TRAF6 is activated by these 
stimuli has important clinical implications for autoimmune disease, osteoporosis, and 
cancer.  
        It is well known that LPS and IL-1 act through TLR4 and IL-IR to induce TRAF6 
autoubiquitination and oligomerization, which are considered as readouts for TRAF6 
activation[33]. Previously our lab showed that IGF-1 also induces TRAF6 
autoubiquitination and tyrosine phosphorylation. Additionally, phosphorylation is a 
critical regulatory mechanism for other TRAF member proteins. These suggest that 
TRAF6 function may also be regulated by phosphorylation.  
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        The goal of my study is to determine the mechanism by which TRAF6 activation is 
achieved through multiple physiological stimuli.  
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B. RESULT 
3-1. TRAF6 tyrosine phosphorylation is commonly induced by IGF-1R, TLR4/IL-
1R, and RANK 
        Since TRAF6 is activated by various receptor signaling pathways, we rationalized 
that these stimuli drive TRAF6 activation through a common mode. Our previous studies 
provided us with a clue by showing that TRAF6 undergoes tyrosine phosphorylation by 
IGF-1[23,96], although the functional significance of this phosphorylation remains 
unknown. I confirmed in this study that TRAF6 tyrosine phosphorylation was induced by 
IGF-1 stimulation (Figure 3-1A). Next, in order to determine whether TRAF6 tyrosine 
phosphorylation is commonly induced by various stimuli, I examined whether other 
stimuli like LPS, IL-1, and RANKL can also induce TRAF6 tyrosine phosphorylation. 
Notably, I found that LPS, IL-1, and RANKL could readily induce TRAF6 tyrosine 
phosphorylation (Figures 3-1B-D). My data therefore suggest that TRAF6 tyrosine 
phosphorylation can be commonly induced by IGF-1R, TLR4/IL-1R, and RANK.  
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Figure 3-1. TRAF6 undergoes tyrosine phosphorylation upon IGF-1, LPS, IL-1 and 
RANKL stimulation 
(A) PC-3 cells were serum starved for 1 day, treated with or without IGF-1(50 ng/ml) for 
15min, and harvested for immunoprecipitation (IP), followed by immunoblotting (IB) 
analysis. WCE indicates whole-cell extracts; and pTyr, phospho-tyrosine antibody. (B)  
Hep3B cells were treated with or without LPS (5g/ml) for 5min, and harvested for IP 
and IB analysis.  
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3-2. Src tyrosine kinase is responsible for TRAF6 phosphorylation 
        To investigate the physiological role of TRAF6 tyrosine phosphorylation, I sought to 
identify the tyrosine kinase(s) that mediates this phosphorylation. Since TRAF6 
phosphorylation is elicited by various receptors (Figures 3-1A-D), we reasoned that the 
kinase(s) triggering TRAF6 tyrosine phosphorylation would be downstream of these 
receptors and involved in Akt and NF-κB signaling pathways. To identify potential 
TRAF6 kinase(s) I analyzed the TRAF6 protein sequence using Phosphomotif finder 
program. Examining the TRAF6 sequence revealed that several putative kinase motifs are 
within the TRAF6 sequence including EGFR, JAK2, and Src kinase (Figure 3-2A). 
Among these candidate kinases, we suspected that Src tyrosine kinase may be a kinase 
for TRAF6, as it has been implicated in Akt and NF-κB signaling activation 
[67,100,101,102,103,104,105,106]. To test this hypothesis, I first examined if there is an 
inducible interaction between TRAF6 and Src in response to IGF-1 stimulation. I found 
that indeed the interaction between Src and TRAF6 was induced within 15 min of IGF-1 
stimulation and gradually declined after 30 min of treatment (Figure 3-2B). I next 
performed in vitro and in vivo kinase assays to examine whether Src is a kinase for 
TRAF6. Expression of constitutive active form of Src (Src Y527F) increased Src 
autophosphorylation on Y416, an active mark for Src kinase activation, and TRAF6 
tyrosine phosphorylation, whereas expression of kinase-dead form of Src (K295R) failed 
to do so (Figure 3-2C). In vitro kinase assay revealed that recombinant active Src kinase 
readily induced TRAF6 tyrosine phosphorylation (Figure 3-2D). Furthermore, notably, 
Src
-/-
 mouse embryonic fibroblasts (MEFs) failed to induce TRAF6 phosphorylation 
compared to wild-type (WT) MEFs upon IGF-1 stimulation (Figure 3-2E). Accordingly, 
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these results suggest that Src is a direct kinase that mediates TRAF6 tyrosine 
phosphorylation. 
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Figure 3-2. Src tyrosine kinase is responsible for TRAF6 phosphorylation 
(A)Potential kinase motifs within the TRAF6 protein sequence using the Phosphomotif 
finder program. Motif scan results from Human Protein Reference Database at 
http://www.hprd.org.  
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Figure 3-2. Src tyrosine kinase is responsible for TRAF6 phosphorylation 
(B) Association of TRAF6 with Src is induced upon IGF-1 treatment. PC-3 cells were 
serum-starved for 1 day, treated with IGF-1 for indicated time points, and collected for 
co-immunoprecipitation assay, followed by IB analysis.  
 
 
 
 
 
39 
 
                                                     
                                         
 
Figure 3-2. Src tyrosine kinase is responsible for TRAF6 phosphorylation 
(C) In vivo Src kinase assay. HEK 293T cells were transfected with Flag-TRAF6, Src-
Y527F (constitutive active form), and Src-Y295R (kinase dead), and collected for IP, 
followed by IB analysis. (D) In vitro Src kinase assay. GST-TRAF6 proteins were 
incubated with recombinant active Src for 15min, followed by IB analysis.  
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Figure 3-2. Src tyrosine kinase is responsible for TRAF6 phosphorylation 
(E) Wild type (WT) and Src
-/-
 mouse embryonic fibroblasts (MEFs) were serum-starved 
for 24hrs, treated with or without 100ng/ml of IGF-1 for 15min, and harvested for IP, 
followed by IB analysis. 
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3-3. Src tyrosine kinase phosphorylates TRAF6 at Y473  
        In order to determine the function of TRAF6 tyrosine phosphorylation, I examined 
which tyrosine residue of TRAF6 is phosphorylated by Src kinase. For this aim I mutated 
all tyrosine residues within the TRAF6 sequence to non-phosphorylatable phenylalanine 
(F) or phosphomimetic glutamic acid (E) or aspartic acid (D), and subsequently carried 
out in vivo Src kinase assay with these TRAF6 mutants. Src-mediated TRAF6 
phosphorylation was more significantly reduced on the Y473F mutant compared to 
TRAF6 WT and other TRAF6 mutants (Figure 3-3A).  Interestingly, Y473 residue of 
TRAF6 is highly conserved among species and located within TRAF6 substrate binding 
motif (Figure 3-3B) [107].  Importantly, in vitro kinase assay confirmed that Src-
mediated TRAF6 tyrosine phosphorylation was significantly reduced in the TRAF6 
Y473F mutant (Figure 3-3C), suggesting that TRAF6 Y473 residue is a major 
phosphorylation site for Src kinase. To further validate these results, I generated a 
phospho-specific antibody against Y473 tyrosine phosphorylation of TRAF6. In vitro and 
in vivo kinase assays indeed confirmed that TRAF6 Y473 phosphorylation was induced 
by Src kinase (Figures 3-3D and 3E). I further showed that this phospho-TRAF6 antibody 
is specific for TRAF6 Y473 phosphorylation since this antibody detected the signal in 
TRAF6 WT, but not in TRAF6 Y473F mutant (Figures 3-3D and 3E). 
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Figure 3-3. Src tyrosine kinase phosphorylates TRAF6 at Y473 residue.  
 (A) Identification of Src-mediated TRAF6 Phosphorylation Site. HEK 293T cells were 
transfected with indicated plasmids and harvested for IP, followed by IB analysis. C70A 
indicates TRAF6 C70A mutant, which loses E3 ligase activity and Src CA indicates Src 
constitutive active form (Src Y527F). (B) Alignment of TRAF6 proteins among species. 
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Figure 3-3. Src tyrosine kinase phosphorylates TRAF6 at Y473 residue 
(C) In vitro Src kinase assay. GST-TRAF6 and GST-TRAF6 Y473F were incubated with 
recombinant active Src for 15 min, followed by IB analysis. (D) In vitro Src kinase assay 
with anti-pTRAF6 (Y473) antibody. Recombinant GST-TRAF6 proteins were incubated 
with recombinant active Src for 15min, followed by IB analysis with indicated antibody.  
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Figure 3-3. Src tyrosine kinase phosphorylates TRAF6 at Y473 residue 
(E) In vivo Src kinase assay with anti-pTRAF6 (Y473) antibody. HEK 293T cells were 
transfected with Flag-TRAF6, Src-Y527F, and Src-Y295R, and harvested for IP, 
followed by IB analysis with indicated antibody. 
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3-4. TRAF6 Y473 phosphorylation is induced by IGF-1, LPS, IL-1 and RANKL 
stimulation in a Src tyrosine kinase dependent manner.         
        Since various receptors trigger TRAF6 tyrosine phosphorylation (Figures 3-1A-D), I 
determined whether TRAF6 Y473 phosphorylation can also be induced by these receptor 
signaling, and if so, it is Src-dependent. To this end, I stimulated WT MEFs and Src
-/- 
MEFs with different ligands and preformed the immunoblotting assay. Notably, I found 
that Y473 phosphorylation of TRAF6 was induced by IGF-1, LPS, IL-1, and RANKL in 
WT MEFs, but not in Src
-/- 
MEFs (Figures 3-4A-D). I further confirmed that TRAF6 
Y473 phosphorylation induced by IGF-1, LPS, and IL-1 could be seen in other cell lines 
(Figures 3-4E-G). Moreover, I found that RANKL also induced TRAF6 Y473 
phosphorylation in Raw 264.7 cells, which was significantly blocked by a Src inhibitor, 
PP2 (Figure 3-4H), suggesting that Src is involved in TRAF6 Y473 phosphorylation 
upon RANKL stimulation, although  kinase(s) other than Src may be also involved. 
These results suggest that Y473 tyrosine phosphorylation is commonly induced by 
diverse stimuli in a Src-dependent manner.  
        Intriguingly, I found that Src was activated not only by IGF-1 and RANKL, but also 
LPS and IL-1, which is correlated to Akt, IKK-NF-κB, and JNK activation (Figures 3-
4A-H). Notably, Src deficiency or inhibition impaired activation of Akt, IKK-NF-kB, and 
JNK in response to IGF-1, LPS, IL-1, and RANKL (Figures3-4A-H), consistent with 
previous reports showing that Src kinase inhibitor, PP1 and PP2 inhibited LPS- or IL-1 
induced NF-κB activation [102,103,104]. Accordingly, these results suggest that Src is 
activated by distinct stimuli and is required for TRAF6 Y473 phosphorylation, Akt, IKK-
NF-κB, and JNK activation. 
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Figure 3-4. Diverse stimuli commonly induce TRAF6 Y473 phosphorylation in a Src 
dependent manner  
(A) IGF-1 induces TRAF6 Y473 phosphorylation in a Src tyrosine kinase dependent 
manner. WT and Src
-/-
 MEFs were serum-starved, stimulated with IGF-1 for indicated 
time points, and harvested for IB analysis.  
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Figure 3-4. Diverse stimuli commonly induce TRAF6 Y473 phosphorylation in a Src 
dependent manner  
 (B) LPS induces TRAF6 Y473 phosphorylation in a Src tyrosine kinase dependent 
manner. WT and Src
-/-
 MEFs were stimulated with LPS (5g/ml) for indicated times, and 
collected for IB analysis.  
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Figure 3-4. Diverse stimuli commonly induce TRAF6 Y473 phosphorylation in a Src 
dependent manner  
 (C) IL-1 induces TRAF6 Y473 phosphorylation in a Src tyrosine kinase dependent 
manner. WT and Src
-/-
 MEFs were stimulated with murine IL-1 (10ng/ml) and collected 
for IB analysis.  
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Figure 3-4. Diverse stimuli commonly induce TRAF6 Y473 phosphorylation in a Src 
dependent manner  
(D) RANKL induces TRAF6 Y473 phosphorylation in a Src tyrosine kinase dependent 
manner. WT and Src
-/-
 MEFs were stimulated with RANKL (100ng/ml) for indicated 
times, and collected for IB analysis. 
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Figure 3-4. Diverse stimuli commonly induce TRAF6 Y473 phosphorylation in a Src 
dependent manner  
(E) HEK 293 cells were serum-starved for 1 day, treated with IGF-1 for indicated time 
points, collected for IP, and followed by IB analysis. 
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Figure 3-4. Diverse stimuli commonly induce TRAF6 Y473 phosphorylation in a Src 
dependent manner  
 (F) Hep3B cells were treated with LPS for indicated time points, harvested for IP, and 
followed by IB analysis.  
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Figure 3-4. Diverse stimuli commonly induce TRAF6 Y473 phosphorylation in a Src 
dependent manner  
 (G) Hep3B cells were treated with IL-1 for indicated time points, harvested for IP, and 
followed by IB analysis. 
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Figure 3-4. Diverse stimuli commonly induce TRAF6 Y473 phosphorylation in a Src 
dependent manner  
(H) Src family tyrosine kinase inhibitor, PP2 inhibits induction of TRAF6 Y473 
phosphorylation upon RANKL stimulation. Raw264.7 cells were pretreated with or 
without PP2 (10 μM) for 3 hr, stimulated with RANKL (100ng/ml) and harvested for IB 
analysis. L stands for long exposure and S stands for short exposure.  
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3-5. TRAF6 Y473 phosphorylation is critical for Akt, JNK, and IKK activation 
        TRAF6 E3 ligase activity is required for Akt, JNK, and IKK activation in response 
to various growth factors and cytokines [23,98]. Because TRAF6 Y473 phosphorylation 
is induced by various stimuli, I next determined whether TRAF6 Y473 phosphorylation 
is essential for Akt, JNK, and IKK activation upon diverse stimuli by restoring Mock, 
TRAF6 WT, TRAF6 Y473D, or TRAF6 Y473F into Traf6
-/-
 MEFs. Remarkably, viral 
reconstitution of TRAF6 WT or phospho-mimetic Y473D mutant into Traf6
-/-
 MEFs 
could rescue Akt phosphorylation and activation defects, as determined by Foxo3a 
phosphorylation, upon IGF-1 stimulation, whereas restoration of the TRAF6 Y473F 
mutant could not (Figure 3-5A). Similarly, restoration of TRAF6 WT and 
phosphomimetic Y473E, but not Y473F, in HEK293 cells with TRAF6 knockdown could 
also rescue Akt phosphorylation upon IGF-1 stimulation (Figure 3-5B). Moreover, 
reconstitution of TRAF6 WT or Y473D, but not Y473F, in Traf6
-/-
 MEFs also rescued 
the defect in IKK and JNK activation upon stimulation with LPS, IL-1, or RANKL 
(Figures 3-5C-E). These results highlight the critical role of TRAF6 Y473 
phosphorylation in TRAF6-mediated Akt, JNK and IKK activation by distinct 
physiological stimuli.  
        I have shown that Src induces TRAF6 Y473 phosphorylation and is required for 
Akt, IKK, and JNK activation in response to multiple stimuli including IGF-1, IL-1, LPS, 
and RANKL. Given that TRAF6 Y473 phosphorylation is required for TRAF6-mediated 
Akt, JNK, and IKK activation, I speculated that Src may mediate activation of JNK and 
IKK by inducing TRAF6 Y473 phosphorylation. I indeed supported this notion by 
showing that ectopic expression of phospho-mimetic mutant TRAF6 Y473E, but not 
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phosphorylation-dead mutant TRAF6 Y473F, rescued the defect in IKK and JNK 
activation upon stimulation with LPS or IL-1 (Figures 3-5F and G). My data therefore 
offers the first insight into Src regulation of IKK, JNK activation in response to diverse 
stimuli.   
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Figure 3-5. TRAF6 Y473 phosphorylation is required for Akt, IKK and JNK 
activation.  
(A) TRAF6 Y473 is required for TRAF6-mediated Akt activation. Traf6
-/-
 MEFs 
retrovirally reconstituted with empty vector (Mock) or the indicated Flag-TRAF6 
constructs were serum starved overnight, treated with IGF-1 (100ng/ml) for indicated 
time points, and harvested for IB analysis.  
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Figure 3-5. TRAF6 Y473 phosphorylation is required for Akt, IKK and JNK 
activation.  
 (B) TRAF6 knockdown HEK 293 cells were transfected with indicated plasmids, serum-
starved for 1day, stimulated with IGF-1, and harvested for IB analysis. 
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Figure 3-5. TRAF6 Y473 phosphorylation is required for Akt, IKK and JNK 
activation.  
(C) TRAF6 Y473 phosphorylation is required for TRAF6-mediated IKK and JNK 
activation upon LPS stimulation. Traf6
-/-
 MEFs retrovirally reconstituted with empty 
vector (Mock) or the indicated Flag-TRAF6 constructs were treated with LPS (5μg/ml) 
and harvested for IB analysis.  
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Figure 3-5. TRAF6 Y473 phosphorylation is required for Akt, IKK and JNK 
activation.  
(D) TRAF6 Y473 phosphorylation is required for TRAF6-mediated IKK and JNK 
activation upon IL-1 stimulation. Traf6
-/-
 MEFs retrovirally reconstituted with empty 
vector (Mock) or the indicated Flag-TRAF6 constructs were stimulated with murin IL-1 
(20 ng/ml) and followed by IB analysis.  
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Figure 3-5. TRAF6 Y473 phosphorylation is required for Akt, IKK and JNK 
activation.  
(E) TRAF6 Y473 phosphorylation is required for TRAF6-mediated IKK and JNK 
activation upon RANKL stimulation. Traf6
-/-
 MEFs retrovirally reconstituted with empty 
vector or the indicated Flag-TRAF6 constructs were treated with RANKL (100 ng/ml) for 
indicated times.  
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Figure 3-5. TRAF6 Y473 phosphorylation is required for Akt, IKK and JNK 
activation.  
(F) Src mediates activation of JNK and IKK by inducing TRAF6 Y473 phosphorylation 
upon LPS stimulation.  Src
-/-
 MEF cells were transfected with indicated mock, Flag-
TRAF6 Y473E and Flag-TRAF6 Y473F plasmids, stimulated with 5 μg/ml LPS for 
indicated time points and collected for IB analysis.  
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Figure 3-5. TRAF6 Y473 phosphorylation is required for Akt, IKK and JNK 
activation.  
(G) Src mediates activation of JNK and IKK by inducing TRAF6 Y473 phosphorylation 
upon IL-1 stimulation. Src
-/-
 MEF cells were transfected with indicated mock, Flag-
TRAF6 Y473E and Flag-TRAF6 Y473F plasmids, stimulated with 20ng/ml of murin IL-
1 for indicated time points and collected for IB analysis. 
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3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by enhancing 
its oligomerization and UBC13 binding 
        The finding that TRAF6 Y473 phosphorylation is critical for Akt, IKK, and JNK 
activation upon diverse stimuli suggests that TRAF6 Y473 phosphorylation is required 
for TRAF6 E3 ligase activation. To test this notion, I examined whether mutation of 
TRAF6 Y473 affects its E3 ligase activity by examining TRAF6 autoubiquitination, a 
readout for TRAF6 activation, and ubiquitination of Akt, a substrate of TRAF6 [23]. 
While TRAF6 WT and TRAF6 Y473E displayed substantial autoubiquitination, the 
TRAF6 Y473F mutant profoundly lost this autoubiquitination ability (Figure 3-6A). 
Interestingly, I found that TRAF6 Y473E mutant displayed even higher 
autoubiquitination compared to TRAF6 WT (Figure 3-6A). Similarly, TRAF6 WT and 
TRAF6 Y473E, but not TRAF6 Y473F, promoted ubiquitination of Akt (Figure 3-6B). 
These results suggest that TRAF6 Y473 phosphorylation is critical for TRAF6 E3 ligase 
activation.  
        TRAF6 exists as a dimer and/or an oligomer in cells, which is a prerequisite for 
TRAF6 E3 ligase activity [108,109]. Because TRAF6 Y473 residue resides in TRAF-C 
domain, which mediates TRAF6 oligomerization [110], and interaction with upstream 
activators and downstream effectors [107], we envisioned that Y473 phosphorylation 
may be required for the formation of TRAF6 dimer and/or oligomerization, thereby 
regulating TRAF6 E3 ligase activity. To test this notion, I determined whether mutation 
of Y473 residue affects TRAF6 dimerization and/or oligomerization by using a well-
established BMH cross-linking method [111,112,113,114]. I found that oligomerization 
of TRAF6 or TRAF6 Y473D, but not of TRAF6 Y473F, was induced upon IGF-1 
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stimulation (Figure 3-6C). Remarkably, upon LPS or IL-1 treatment, while most of 
TRAF6 Y473F was maintained in the monomer condition, the formation of TRAF6 
dimer, trimer, and oligomer was increased in TRAF6 wild type (Figures 3-6D and 3-6E). 
These results suggest that Y473 phosphorylation is required for TRAF6 dimerization 
and/or oligomerization in response to diverse stimuli. I confirmed these results by co-
immunoprecipitation assay using two different HA- and Flag-tagged TRAF6 constructs 
(Figures 3-6F and 3-6G). Similarly upon IGF-1 stimulation, induction of TRAF6 
dimerization decreased in TRAF6 Y473F mutant in comparison to TRAF6 WT and 
TRAF6 Y473D.   
        Since TRAF6 autoubiquitination and activation are also dependent on its association 
with ubiquitin-conjugating enzyme (E2) UBC13 [115], I examined whether TRAF6 
Y473 phosphorylation regulates the interaction between TRAF6 and UBC13. Co-
immunoprecipitation assay showed that while TRAF6 WT or TRAF6 Y473E interacts 
with UBC13, TRAF6 Y473F does not (Figure 3-6H). Notably, LPS or IL-1 treatment 
induced the interaction of UBC13 with TRAF6 wild type, but not with TRAF6 Y473F 
(Figures 3-6I and 3-6J). Thus, TRAF6 Y473 phosphorylation mediates the interaction 
between TRAF6 and UBC13 in response to stimuli.  
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Figure 3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its oligomerization and UBC13 binding 
(A) In vivo TRAF6 ubiquitination assay in HEK 239T cells co-transfected with His-
ubiquitin (His-Ub) along with indicated Flag-TRAF6 plasmids, and harvested for nickel 
bead precipitation, followed by IB analysis. Ni-nitrilotriacetic acid (NTA) indicates 
nickel bead precipitate. C70A indicates TRAF6 C70A mutant, which loses E3 ligase 
activity  
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Figure 3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its oligomerization and UBC13 binding 
 (B) In vivo Akt ubiquitination assay in 293T cells co-transfected with His-Ub along with 
indicated Flag-TRAF6 plasmids, and harvested for nickel bead precipitation, followed by 
IB analysis. C70A indicates TRAF6 C70A mutant, which loses E3 ligase activity  
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Figure 3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its oligomerization and UBC13 binding 
(C) TRAF6 Y473 phosphorylation affects TRAF6 oligomerization upon IGF-1 
stimulation. Traf6
-/-
 MEFs retrovirally-reconstituted with empty vector or the indicated 
Flag-TRAF6 constructs were serum starved and treated with IGF-1 (100 ng/ml) for 15 
min. Cells were then lysed, incubated with 0.2 mM BMH cross-linker at room 
temperature for 1hr and followed by immunoblotting analysis. 
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Figure 3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its oligomerization and UBC13 binding 
(D) TRAF6 Y473 phosphorylation affects TRAF6 oligomerization upon LPS stimulation. 
Traf6
-/-
 MEFs retrovirally-reconstituted with empty vector or the indicated Flag-TRAF6 
constructs were treated with LPS (5 μg/ml) for 5 min. Cells were then lysed, incubated 
with BMH cross-linker for 1hr and followed by immunoblotting analysis.  
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Figure 3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its oligomerization and UBC13 binding 
 (E) TRAF6 Y473 phosphorylation affects TRAF6 oligomerization upon IL-1 
stimulation. Traf6
-/-
 MEFs retrovirally-reconstituted with empty vector or the indicated 
Flag-TRAF6 constructs were treated with IL-1 (20 ng/ml) for 5 min. Cells were then 
lysed, incubated with BMH cross-linker for 1hr and followed by immunoblotting 
analysis. 
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Figure 3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its oligomerization and UBC13 binding 
(F) TRAF6 Y473 phosphorylation affects TRAF6 dimerization upon IGF-1 stimulation. 
HEK 293 cells were transfected with empty vector or indicated Flag-TRAF6 and HA-
TRAF6 plasmids, serum starved for 1 day, stimulated with IGF-1 and harvested for co-
IP, followed by IB analysis. 
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Figure 3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its oligomerization and UBC13 binding 
 (G) TRAF6 Y473 phosphorylation affects TRAF6 dimerization. HEK 293T cells were 
transfected with empty vector or indicated Flag-TRAF6 and HA-TRAF6 plasmids, and 
harvested for co-IP, followed by IB analysis. 
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Figure 3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its oligomerization and UBC13 binding 
(H) TRAF6 Y473 phosphorylation regulates the interaction between TRAF6 and UBC13. 
HEK 293T cells were transfected with empty vector or indicated Flag-TRAF6 plasmids, 
and harvested for co-IP, followed by IB analysis.  
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Figure 3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its oligomerization and UBC13 binding 
(I) TRAF6 Y473 phosphorylation regulates the interaction between TRAF6 and UBC13 
upon LPS stimulation. Traf6
-/-
 MEFs retrovirally-reconstituted with empty vector or 
indicated Flag-TRAF6 constructs were treated without or with LPS (5 μg/ml) for 5 min 
and harvested for IP and IB analysis. 
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Figure 3-6. TRAF6 Y473 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its oligomerization and UBC13 binding 
 (J) TRAF6 Y473 phosphorylation regulates the interaction between TRAF6 and UBC13 
upon IL-1 stimulation. Traf6
-/-
 MEFs retrovirally-reconstituted with empty vector or the 
indicated Flag-TRAF6 constructs were treated without or with IL-1 (20 ng/ml) for 5 min. 
Cells were then harvested for IP, followed by IB analysis. 
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3-7. TRAF6 Y473 phosphorylation is required for TRAF6-mediated cell   
proliferation, migration and tumorigenesis 
        We have previously shown that TRAF6 depletion reduces tumorigenic potential in 
PC-3 prostate cancer cell model [101]. In order to determine whether TRAF6 
phosphorylation regulates TRAF6-mediated oncogenic potential in various cancer cell 
models, I generated PC-3, Hep3B, and MDA-MB-231 cancer cells with stable expression 
of Mock, TRAF6, TRAF6 Y473D, or TRAF6 Y473F. I found that overexpression of 
TRAF6 wild type or Y473D, but not TRAF6 Y473F, promoted cell proliferation, 
migration, and invasion in PC-3 prostate cancer cell model (Figures3-7A-7C). Similarly, 
I also found that overexpression of TRAF6 wild type or Y473D, but not TRAF6 Y473F, 
promoted cell proliferation and migration in Hep3B liver cancer cells and MDA-MB-231 
breast cancer cells (Figures3-7D-7G). Notably, overexpression of TRAF6 WT or TRAF6 
Y473D markedly promoted cancer development in the xenograft mouse model, but 
TRAF6 Y473F overexpression failed to do so (Figure 3-7H). These results suggest that 
TRAF6 phosphorylation is imperative for TRAF6-mediated cancer cell proliferation, 
migration, invasion, and tumorigenesis.   
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Figure 3-7. TRAF6 Y473 phosphorylation is critical for TRAF6-mediated cell 
proliferation, migration and tumorigenesis  
(A) Cell proliferation of PC-3 prostate cancer cells infected with mock, TRAF6, TRAF6 
Y473D, and TRAF6 Y473F retrovirus vectors. The quantified results are shown as means 
 SD (n=3), **P0.01. 
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Figure 3-7. TRAF6 Y473 phosphorylation is critical for TRAF6-mediated cell 
proliferation, migration and tumorigenesis  
(B) Transwell migration assay in PC-3 cells infected with mock, TRAF6, TRAF6 
Y473D, and TRAF6 Y473F retroviral vectors. The quantified results are shown as means 
 SD (n=3), **P0.01; ***P0.001. Scale bar represents 100μm. 
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Figure 3-7. TRAF6 Y473 phosphorylation is critical for TRAF6-mediated cell 
proliferation, migration and tumorigenesis  
(C) Transwell invasion assay in PC-3 cells infected with mock, TRAF6, TRAF6 Y473D, 
and TRAF6 Y473F retroviral vectors. The quantified results are shown as means  SD 
(n=3), **P0.01; ***P0.001. Scale bar represents 100μm.  
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Figure 3-7. TRAF6 Y473 phosphorylation is critical for TRAF6-mediated cell 
proliferation, migration and tumorigenesis  
(D) Cell proliferations of Hep3B liver cancer cells infected with mock, TRAF6, TRAF6 
Y473D, and TRAF6 Y473F retrovirus vectors. The quantified results are shown as means 
 SD (n=3), **P0.01.                                        
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Figure 3-7. TRAF6 Y473 phosphorylation is critical for TRAF6-mediated cell 
proliferation, migration and tumorigenesis  
(E) Transwell migration assay in Hep3B cells infected with mock, TRAF6, TRAF6 
Y473D, and TRAF6 Y473F retrovirus vectors. The quantified results are shown as means 
 SD (n=3), ***P0.001. Scale bar represents 200μm. 
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Figure 3-7. TRAF6 Y473 phosphorylation is critical for TRAF6-mediated cell 
proliferation, migration and tumorigenesis  
(F) Cell proliferations of MDA-MB-231breast cancer cells infected with mock, TRAF6, 
TRAF6 Y473D, and TRAF6 Y473F retrovirus vectors. The quantified results are shown 
as means  SD (n=3), **P0.01. 
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Figure 3-7. TRAF6 Y473 phosphorylation is critical for TRAF6-mediated cell 
proliferation, migration and tumorigenesis  
(G) Transwell migration assay in MDA-MB-231 cells infected with mock, TRAF6, 
TRAF6 Y473D, and TRAF6 Y473F retrovirus vectors. The quantified results are shown 
as means  SD (n=3), ***P0.001. Scale bar represents 200μm. 
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Figure 3-7. TRAF6 Y473 phosphorylation is critical for TRAF6-mediated cell 
proliferation, migration and tumorigenesis  
(H) PC-3 cells infected with mock, TRAF6, TRAF6 Y473D, and TRAF6 Y473F 
retrovirus vectors were injected into nude mice and monitored for tumorigenesis. The 
quantified results are shown as means  SD (n=6), **P0.01; ***P0.001. 
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3-8. TRAF6 Y473 phosphorylation is highly correlated with activation of Src, Akt 
and IKK and predicts poor survival outcome and metastasis-free survival in breast 
carcinoma patients. 
        Since TRAF6 Y473 phosphorylation regulated TRAF6-mediated oncogenic 
potential in various cell models and xenograft mouse model, we next investigated 
whether TRAF6 Y473 phosphorylation correlates with activation of Src, Akt, and IKK in 
the human cancer samples. To achieve this aim we carried out immunohistochemistry 
analysis to determine whether the expression level of TRAF6 Y473 phosphorylation and 
correlation with Src, Akt, and IKK activation in the cohort of breast cancer samples using 
phospho-TRAF6 (Y473), phospho-Src (Y416), phospho-Akt (S473), and phospho-
IKK/ (S176/180) antibodies. In the 212 breast carcinoma samples, elevated expression 
both phospho-Src (Y416) and phospho-TRAF6 (Y473) was significantly associated with 
increments of primary tumor status (pT, p=0.024 and 0.013, respectively), nodal 
metastasis (pN, p=0.024 and 0.044, respectively), and stage (p=0.031 and 0.004, 
respectively). High phospho-Akt (S473) expression was also associated with the presence 
of nodal metastasis (p=0.034). Interestingly, the phospho-IKKα/β (S176/180) high 
expression also positively correlated with increments in nodal status (p-0.0010) and 
tumor stage (p=0.012) (Table 3-1). As summarized in Table 3-2, Figures 3-8A-D, 
phospho-Src (Y416) expression was positively associated with phospho-TRAF6 (Y473) 
(r=0.515, p<0.001), phospho-Akt (S473) (r=0.454, p<0.001), and phospho-IKKα/β 
(S176/180) expression (r=0.528, p<0.001). Phospho-TRAF6 (Y473)
 
expression was also 
significantly associated with phospho-Akt (S473) (r=0.272, p<0.001) and phospho-
IKKα/β (S176/180) (r=0.367, p<0.001) expression (Figures 3-8 E and F). Importantly, 
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expression of all phospho-Src (Y416), phopho-TRAF6 (Y416), phopho-Akt (S473), and 
phospho-IKKα/β (S176/180) significantly predicted disease-specific (DSS) and 
metastasis-free survival (MeFS), as summarized in Table 3-3, Figures 3-8 G-J together 
with pT status, pN status, and stage.  In the multivariate analysis, high expression of 
phospho-Src (Y416) (p=0.001) and phopho-TRAF6 (Y473) (p=0.018), together with 
higher stage (p<0.001) remained to be prognostically significant for MeFS (Table 3-4). 
Only tumor stage independently predicted DSS. These results underscore the importance 
of TRAF6 Y473 phosphorylation and Src activation in breast cancer progression and 
disease outcome.  
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Table 3-1. Associations between pSrc, pTRAF6, pAkt, and pIkkα/β expressions with 
important clinicopathologic variables. 
Parameters Category Case No. pSrc LI pTRAF6 LI pAkt LI pIkkα/β LI 
H-Score p-value H-Score p-value H-Score p-value H-Score p-value 
Primary tumor 
(T)# 
T1 90 195.3±66.4 0.024* 208.9±63.9 0.013* 216.6±56.6 0.116 191.1±57.8 0.323 
 T2 97 212.9±87.4  228.5±63.6  222.6±61.8  202.7±64.1  
 T3-T4 25 246.8±74.7  250.8±61.1  240.6±64.2  205.4±55.4  
Nodal status 
(N)& 
N0 123 197.4±71.7 0.024* 215.2±65.1 0.044* 214.8±55.6 0.034* 1898.9±59.6 0.010* 
 N1-N2 89 226.2±85.5  233.3±62.9  232.4±64.7  209.4±60.3  
Stage& I 69 189.5±64.4 0.031* 204.5±67.0 0.004* 213.2±53.832 0.234 182.5±54.1 0.012* 
 II-III 143 226.5±83.5  231.6±61.8  226.5±62.628  205.6±62.2  
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Table 3-2. Associations between pSrc, pTRAF6, pAkt, and pIkkα/β expressions in 
breast cancer  
Parameters pSrc LI pTRAF6 LI pAkt LI 
 Correlation 
coefficient 
p-value Correlation 
coefficient 
p-value Correlation 
coefficient 
p-value 
pTRAF6 LI r=0.515 <0.001* - - - - 
pAkt LI r=0.454 <0.001* r=0.272 <0.001* - - 
pIkkα/β LI r=0.528 <0.001* r=0.367 <0.001* r=0.271 <0.001* 
Pearson’s correlation coefficient test; *, Statistically significant 
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Figure 3-8. TRAF6 Y473 phosphorylation is highly correlated with Src, Akt and 
IKK activation and predicts poor survival outcome in breast cancer patients 
(A) Immunohistochemistry analysis of phospho-TRAF6 (Y473), phospho-Src (Y416), 
phospho-Akt (S473), and phospho-IKK/ (S176/180) in breast carcinoma samples.  
Scale bar represents 200μm.  
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Figure 3-8. TRAF6 Y473 phosphorylation is highly correlated with Src, Akt and 
IKK activation and predicts poor survival outcome in breast cancer patients 
(B) Positive correlation between phopho-TRAF6 (Y473) and phospho-Src (Y416) in 
histological score. 
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Figure 3-8. TRAF6 Y473 phosphorylation is highly correlated with Src, Akt and 
IKK activation and predicts poor survival outcome in breast cancer patients 
(C) Positive correlation between phospho-Src (Y416) and phospho-Akt (S473).  
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Figure 3-8. TRAF6 Y473 phosphorylation is highly correlated with Src, Akt and 
IKK activation and predicts poor survival outcome in breast cancer patients 
(D) Positive correlation between phospho-Src (Y416) and phospho-IKK/ (S176/180). 
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Figure 3-8. TRAF6 Y473 phosphorylation is highly correlated with Src, Akt and 
IKK activation and predicts poor survival outcome in breast cancer patients 
(E) Positive correlation between phospho-TRAF6 (Y473) and phospho-Akt (S473). 
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Figure 3-8. TRAF6 Y473 phosphorylation is highly correlated with Src, Akt and 
IKK activation and predicts poor survival outcome in breast cancer patients 
(F) Positive correlation between phospho-TRAF6 (Y473) and phospho-IKK/ 
(S176/180). 
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Table 3-3. Univariate survival analyses 
Parameters Category DSS MeFS 
HR (95% CI) p-value HR (95% CI) p-value 
Primary tumor (T) T1 vs. T2 vs. T3-T4 2.159 (1.067-4.348) 0.032* 3.934 (2.680-5.775) <0.001* 
Nodal status (N) N0 vs. N1-N2 3.946 (1.550-10.043) 0.004* 4.873 (2.796-8.492) <0.001* 
Stage Stage I vs. Stage II vs. Stage III 4.886 (2.278-10.483) <0.001* 4.708 (3.079-7.2004) <0.001* 
pSrc LI Continuous 1.011 (1.005-1.016) <0.001* 1.010 (1.007-1.013) <0.001* 
pTRAF6 LI Continuous  1.013 (1.006-1.021) <0.001* 1.012 (1.008-1.016) <0.001* 
pAkt LI Continuous  1.009 (1.003-1.014) 0.001* 1.007 (1.004-1.010) <0.001* 
pIkkα/β LI Continuous  1.011 (1.005-1.018) 0.001* 1.006 (1.003-1.010) 0.001 
pSrc LI Low (<median) vs. High 
(>=median) 
- 0.0052* - <0.0001* 
pTRAF6 LI Low (<median) vs. High 
(>=median) 
- 0.0114* - <0.0001* 
pAkt LI Low (<median) vs. High 
(>=median) 
- <0.0001 - <0.0001* 
pIkkα/β LI Low (<median) vs. High 
(>=median) 
- 0.0029* - 0.0398* 
DSS, disease-specific survival; MeFS, metastasis-free survival; *, statistically significant 
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Figure 3-8. TRAF6 Y473 phosphorylation is highly correlated with Src, Akt and 
IKK activation and predicts poor survival outcome in breast cancer patients 
(G) Kaplan-Meier plot analysis of disease-specific survival of breast carcinoma patient 
samples with low or high expression of phospho-TRAF6 (Y473)  
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Figure 3-8. TRAF6 Y473 phosphorylation is highly correlated with Src, Akt and 
IKK activation and predicts poor survival outcome in breast cancer patients 
 (H) Kaplan-Meier plot analysis of disease-specific survival of breast carcinoma patient 
samples with low or high expression of phospho-Src (Y416).  
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Figure 3-8. TRAF6 Y473 phosphorylation is highly correlated with Src, Akt and 
IKK activation and predicts poor survival outcome in breast cancer patients 
(I) Kaplan-Meier plot analysis of metastasis-free survival of breast carcinoma patient 
samples with low or high expression of phospho-TRAF6 (Y473).  
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Figure 3-8. TRAF6 Y473 phosphorylation is highly correlated with Src, Akt and 
IKK activation and predicts poor survival outcome in breast cancer patients 
(J) Kaplan-Meier plot analysis of metastasis-free survival of breast carcinoma patient 
samples with low or high expression of phospho-Src (Y416).  
 
 
 
 
 
99 
 
Table 3-4. Multivariate survival analyses 
Parameters Category DSS MeFS 
  HR (95% CI) p-value HR (95% CI) p-value 
Stage Stage I vs. Stage II vs. Stage III 3.771 (1.491-9.537) 0.005* 3.482 (2.174-5.576) <0.001* 
pSrc LI Continuous  1.005 (0.998-1.013) 0.159 1.007 (1.003-1.011) 0.001* 
pTRAF6 LI Continuous  1.006 (0.997-1.014) 0.187 1.006 (1.001-1.011) 0.018* 
pAkt LI Continuous  0.999 (0.992-1.006) 0.768 0.999 (0.995-1.002) 0.466 
pIkkα/β LI Continuous  1.005 (0.998-1.013) 0.164 1.000 (0.995-1.004) 0.882 
DSS, disease-specific survival; MeFS, metastasis-free survival; *, Statistically significant 
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CHAPTER 4 
DISCUSSION  
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4-1. Diverse receptor signalings trigger TRAF6 activation by Src-mediated TRAF6 
phosphorylation 
        TRAFs are well known cytoplasmic adaptor family proteins that are essential for 
receptor-mediated immune response. Among the TRAFs, TRAF6 is the unique TRAF 
family member involved in TLR-4/IL-1- and TNFR-mediated NF-B and AP-1 
activation, and IGF-1R-mediated Akt activation. Therefore, the proper regulation of 
TRAF6 activity is imperative to maintain and regulate normal cellular response and 
physiology. Although TRAF6 has critical roles in maintaining and regulating normal 
cellular response and physiology, the mechanism by which TRAF6 activation is achieved 
through multiple physiological stimuli remains largely unclear.  
        In my study, we have revealed for the first time the novel molecular mechanism by 
which TRAF6 E3 ligase is activated by diverse receptor signaling stimuli. I have shown 
that distinct stimuli commonly trigger Src activation can also induce TRAF6 tyrosine 
phosphorylation at Y473. The Y473 phosphorylation of TRAF6 represents a critical 
event for TRAF6 dimerization/oligomerization and its binding to E2 UBC13, thereby 
leading to TRAF6 activation. Active TRAF6 then triggers activation of Akt, IKK, and 
JNK to participate in various biological processes such as cell proliferation, migration, 
and tumorigenesis (Figure 4-1).  
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Figure 4-1. Working model.  
Src activation is induced by multiple receptors including IGF-1R, IL-1R, TLR4 and 
RANK.  Src then induces TRAF6 tyrosine phosphorylation at Y473, which serves as a 
critical event for TRAF6 dimerization/oligomerization and its binding to E2 UBC13, 
thereby leading to TRAF6 activation. Active TRAF6 then triggers activation of Akt, IKK 
and JNK to participate in various biological processes such as cell proliferation, 
migration and tumorigenesis 
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4-2. Src tyrosine kinase phosphorylates TRAF6 at Y473 
        Phosphorylation is an important posttranslational modification to regulate TRAF 
proteins in signaling. It is reported that PKN1-mediated TRAF1 S146 phosphorylation 
negatively regulates TNF-R2-dependent NF-κB and JNK signaling activation in HeLa 
cells and T cells [50,51]. Phosphorylation of TRAF2 by PKCζ, IKKε, PKCδ, or PKCε 
promotes K63-linked ubiquitination of TRAF2 and NF-κB activation in TNF-R signaling 
and transformed cells [52,53,54,55]. IKKα-mediated TRAF4 S426 phosphorylation upon 
NOD2 activation inhibits NF-κB activation, cytokine production, and antibacterial 
activity in macrophage [56]. 
        In my study, I have also demonstrated that tyrosine phosphorylation is a key 
regulatory mechanism of TRAF6 E3 ligase function in various signaling pathways. I have 
shown that TRAF6 tyrosine phosphorylation is commonly induced by various signaling 
stimuli (Figures.3-1A-1D) and identified that Src is a direct kinase that induces TRAF6 
Y473 phosphorylation (Figures.3-2C-2E). I further showed that this Src-mediated 
TRAF6 Y473 phosphorylation positively regulates TRAF6 E3 ligase function (Figures 3-
6A and 6B). However, I also observed that Src deficiency or inhibition of Src activity 
could not completely abolish TRAF6 Y473 phosphorylation (Figures 3-4A, 4C, and 4D). 
This suggested kinase(s) other than Src may also be involved in this Y473 
phosphorylation. Given that other Src family kinases including Fyn and Syk have shown 
to interact with TRAF6 [100,116], it is highly possible that they may be involved in 
TRAF6 regulation through phosphorylation. Further investigation is needed to explore 
this possibility. 
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4-3. Src tyrosine kinase is required for Akt, IKK and JNK activation 
        Src tyrosine kinase role in Akt activation under diverse growth factor receptors 
[117,118] is widely known. Previous studies have implicated Src in NF-B signaling 
activation upon simulation with IL-1 and LPS [102,103,104]. However, the mechanism 
which Src engages in these diverse signaling pathways is not well understood. Notably, 
my results support and provide important new insights into how Src is engaged in Akt, 
JNK, and IKK/NF-B activation. I have shown that diverse stimuli, such as IGF-1, IL-1, 
LPS, and RANKL, commonly induces Src activation in various cell models, triggers 
TRAF6 tyrosine phosphorylation at Y473 as well to induce TRAF6 activation, in turn 
eliciting activation of Akt, IKK, and JNK (Figures.3-4A-4H).  
        It is valuable to mention that I observed TRAF6 phosphomimetic mutant itself could 
not be constitutively active in the downstream of TRAF6 signaling events in our rescue 
experiments (Figures 3A-3D). IGF-1, LPS, IL-1, and RANKL stimulation are still 
required for Akt, IKK and JNK activation. This suggests that the receptor-dependent 
signaling activation is still required for TRAF6 downstream signaling activation. 
        Because previous study showed that TRAF6 also regulates Src kinase activity in 
RANK signaling pathway [100], I also tested whether Src-mediated TRAF6 
phosphorylation functions as a positive feedback loop for Src activation. Indeed, I 
observed TRAF6 Y473F mutant showed defect in Src activation upon RANKL 
stimulation (unpublished observation). Future investigation is needed to determine 
whether Src-mediated TRAF6 phosphorylation may serve as a positive feedback loop for 
Src activation in other signaling pathway.   
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        In my study, I did not explore the possibility that other physiological stimuli also 
can activate Src/TRAF6 activation. It is known that Src tyrosine kinase is involved in 
multiple receptor tyrosine kinase (RTK) signaling pathways. Src has shown to be 
downstream of IGF-1R, PDGF receptor (PDGF-R), fibroblast growth factor receptor 
(FGF-R), epidermal growth factor receptor (EGF-R), hepatocyte growth factor receptor 
(HGF-R), stem cell factor receptor (SCF-R),colony-stimulatingfactor-1 receptor (CSF-
1R), muscle specific kinase (MuSK)[119,120,121,122,123,124,125,126,127]. Given that 
TNF-α, DNA damage and hypoxia can trigger Src and TRAF6 activation [128,129,130], 
it will be interesting to investigate whether these physiological stimuli can trigger Src-
mediated TRAF6 activation and play critical roles in those pathways.   
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4-4. Src-mediated TRAF6 phosphorylation regulates TRAF6 E3 ligase activity by 
enhancing its dimerization/oligomerization and UBC13 binding 
        TRAF6 dimerization/oligomerization is critical for TRAF6 E3 ligase activity 
[108,109]. Since Src mediated TRAF6 phosphorylation site is located in TRAF-C 
domain, which is known to mediate TRAF6 oligomerization and interaction with 
upstream activators and downstream effectors, I first tested whether mutating the Src-
mediated TRAF6 phosphorylation site would affect their dimerization/oligomerization 
ability. I showed that Src-mediated TRAF6 phosphorylation is critical for its dimerization 
and/or oligomerization in response to diverse stimuli (Figures 3-6C-6H). I further showed 
that Src-mediated TRAF6 phosphorylation also affected TRAF6 interaction with E2 
enzyme, UBC13 (Figures 3-6I and 6J). These findings are conflicted to previous 
independent reports showing that UBC13 interacts with TRAF6 through the N-terminal 
RING and zinc finger as well as the coiled-coil domain [131,132]. How does Src-
mediated TRAF6 phosphorylation regulate UBC13 interaction?  Previous report suggests 
that TRAF6 is autoinhibited by intramolecular interaction between RING-Zinc (RZ) 
region and carboxyl-terminal MATH domain. This inactive closed form can be disrupted 
and converted to an active form, upon binding of proteins containing TRAF interacting 
motif (TIM). In this open active structure, TRAF6 can interact with UBC13 and 
downstream kinases [133]. Because TRAF6 phosphorylation site reside in TRAF6 
substrate binding motif, it is highly possible that Src-mediated TRAF6 phosphorylation 
promotes association with upstream activator proteins leading to open active 
conformation. Indeed, I observed that association of TRAF6 with TRAF6 binding 
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proteins including IRAK-1, and TAB2 is decreased in TRAF6 Y473F mutant in 
comparison to TRAF6 WT and TRAF6 Y473D (unpublished observation).   
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4-5. Src-mediated TRAF6 Y473 phosphorylation is required for oncogenic role of 
TRAF6 
        Although deregulation of NF-κB signaling is involved in human cancer development 
[134,135], it was not clear whether TRAF6 is also related to tumorigenesis until recently, 
our lab showed that TRAF6 depletion decreased Akt activation and reduced tumorigenic 
potential in PC-3 prostate cancer cell model [23].   
        In my study, my data support our previous study and extend our current knowledge 
on the oncogenic role of TRAF6. I have shown that overexpression of TRAF6 wild type 
or Y473D, but not TRAF6 Y473F, promoted cell proliferation, migration, and invasion in 
various cancer cell models (Figures 3-7A-7G). These data suggest Src-mediated TRAF6 
phosphorylation is imperative to regulate TRAF6-mediated cancer cell proliferation, 
migration, invasion, and tumorigenesis. Moreover, I also found that TRAF6 
overexpression promotes cell proliferation and migration not only in PC-3 cells but also 
MDA-MB-231 and Hep3B cells.  My findings are further supported by recent reports. It 
has been reported that TRAF6 is involved in many human cancer including gastric cancer, 
lung cancer, prostate cancer, breast cancer, osteosarcoma and acute myeloid leukemia 
[136,137,138,139,140,141]. 
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4-6. Src-Mediated TRAF6 Y473 phosphorylation is a marker for poor survival 
outcome and a potential therapeutic target for breast cancer 
        It has been well documented that Src activity and Src protein levels are elevated in 
several human cancers including colon and breast cancer [142,143,144,145,146,147]. It is 
also reported that overexpression and gene amplification of TRAF6 are observed in lung 
cancer and osteosarcoma cells [138,140,141]. In my study, my data provide new insights 
into how Src and TRAF6 activations are correlated in human cancer. We showed Src-
mediated TRAF6 tyrosine Y473 phosphorylation is a critical factor for TRAF6-mediated 
oncogenic activity in various cell models and mouse xenograft model. We also showed 
that the clinical relevance of TRAF6 Y473 phosphorylation. We found that Src Y416 and 
TRAF6 Y473 phosphorylation are upregulated in high stage of human breast cancer 
samples and correlate with IKK and Akt activation, supporting the notion that Src-
TRAF6-Akt and Src-TRAF6-IKK pathways are highly activated in advanced human 
breast cancer. Importantly, upregulation of Src Y416 phosphorylation or TRAF6 Y473 
tyrosine phosphorylation predicts poor survival outcome and metastasis-free survival. 
Taken together, our data suggest that Src-mediated TRAF6 Y473 phosphorylation can be 
regarded as a useful biomarker for predicting disease progression and survival outcome 
of breast cancer patients.  
         In summary, my study identifies Src-mediated TRAF6 Y473 phosphorylation as a 
common mode for oncogenic TRAF6 activation and Src-mediated Akt, JNK and IKK 
activation under diverse physiological stimuli. Therefore, pharmacological targeting of 
Src-mediated TRAF6 Y473 phosphorylation may represent an effective strategy for 
cancer therapy. 
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CHAPTER 5 
                 Future direction 
 
 
 
 
 
 
 
111 
 
        TRAF6 is a well-known cytoplasmic mediator protein that is involved in TLR-4/IL-
1R and TNFR-mediated NF-B and AP-1 activation, and IGF-1R-mediated Akt 
activation. Therefore, a number of studies have revealed the importance of TRAF6 in 
maintaining and regulating normal cellular response and physiology. However, the 
mechanism TRAF6 activation is achieved through multiple physiological stimuli remains 
largely unclear.  
        In this study, I demonstrated that TRAF6 Y473 phosphorylation can be commonly 
induced by IGF-1, IL-1, LPS and RANKL, and Src, which is activated by these stimuli, 
acts as a direct kinase for this TRAF6 phosphorylation. Importantly, TRAF6 or Src 
deficiency impairs the activation of Akt, IKK and JNK, and such defects can be rescued 
by phosphomimetic TRAF6, but not phospho-dead mutant TRAF6, suggesting that Src 
induces the activation of Akt, IKK and JNK through promoting TRAF6 Y473 
phosphorylation. Notably, I found that TRAF6 Y473 phosphorylation is required for 
TRAF6 dimerization/oligomerization and its binding to UBC13, a ubiquitin conjugating 
enzyme (E2), in order to activate TRAF6 E3 ligase. Finally, I showed that TRAF6 Y473 
is a critical event for TRAF6-mediated tumorigenesis in mouse models and serves as a 
poor prognosis marker for breast cancer progression and disease outcome. My study, 
therefore, provides an answer to a long-standing puzzle of how TRAF6 activation is 
achieved and of how Src/TRAF6 mediates Akt, IKK and JNK activation in response to 
multiple physiological ligands.  
        However, some important questions still remain to be addressed for future 
investigation. Here, I discuss some of these questions for the future direction. 
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5-1. Can IGF-1R signaling stimulus also trigger IKK/NF-κB activation through Src-
mediated TRAF6 Y473 phosphorylation? 
        In this study, I have shown that Src activation is induced by multiple receptors 
including IGF-1R, IL-1R, TLR4 and RANK. Src then induces TRAF6 tyrosine 
phosphorylation at Y473, which serves as a critical event for TRAF6 activation. Active 
TRAF6 then triggers activation of Akt, IKK and JNK to participate in various biological 
processes such as cell proliferation, migration and tumorigenesis. However, it is still 
unclear whether IGF-1R signaling stimulus can also trigger the IKK/NF-κB activation 
through Src-mediated TRAF6 Y473 phosphorylation.   
        It has been reported that IGF-1R pathway can activate PI-3K/Akt, which in turn 
stimulates NF-κB signaling through phosphorylating and activating the IKK complex 
[148,149]. This upregulation of NF-κB signaling is achieved through several mechanisms 
including stimulating p65 transactivation, as well as phosphorylation and activation of 
IKKβ. Moreover, many reports have shown that Akt phosphorylates and activates IKKα, 
which enhances the processing of p100 to p52 [150,151,152]. Interestingly, it is also 
demonstrated that PDK1 can directly phosphorylate IKKβ and subsequently induce the 
nuclear translocation of NF-κB complexes to turn on the expression of NF-κB target 
genes [153]. My data along with these observations suggest that IGF-1R-driven IKK/NF-
κB activation is achieved through either or both Src/TRAF6/IKK pathway or/and 
PDK1/IKK pathway. Additional investigations are required to determine which pathway 
governs the IGF-1R-driven IKK/NF-B activation. 
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5-2. Are there other kinases or phosphatases also involved in regulation of TRAF6 
activation? 
        Initial TRAF6 sequence analysis revealed that several putative kinase motifs are 
within the TRAF6 sequence including EGFR, JAK2, and Src kinase. Among these 
candidate kinases, I identified, in my study, the Src tyrosine kinase is a direct TRAF6 
kinase that regulates TRAF6 E3 ligase activity through TRAF6 Y473 phosphorylation.  
However, we did not explore the possibility that other kinases or phosphatases are also 
involved in regulation of TRAF6 activity. A recent study showed that the gamma 
catalytic subunit of protein phosphatase 1(PP1-) physically associates with TRAF6 and 
enhances the TRAF6 E3 ligase activity [154]. This result suggests that there might be 
unknown inhibitory phosphorylation sites of TRAF6, E2 enzyme UBC13, or one of its 
substrates, requiring for E3 ligase function. Moreover, given the fact that PP1- is a 
serine/threonine phosphatase, it is also possible that serine/threonine phosphorylation 
event by unknown serine/threonine kinases is also involved in regulation of TRAF6 
activation.  Further investigation will be needed to explore this possibility.   
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5-3. Does the Src-mediated TRAF6 Y473 phosphorylation regulate TRAF6 
localization and activation? 
        Activation of Src kinase is known to associate with its membrane localization, 
shorter disease survival, and increasing tumor size [155,156]. It is also known that upon 
stimulation with IL-1 or a TLR ligand triggers TRAF6 recruitment to the receptor 
through interacting with myddosome complex which consists of adaptor protein MyD88 
and the protein kinases IRAK1 and IRAK4. IRAKs have been reported to recruit TRAF6 
with assistance by a TRAF6-interacting protein with a forkhead-associated domain 
(TIFA) [157,158]. Moreover, another report showed that upon RANKL ligand 
stimulation, TRAF6 directly interacts with RANK, leading to downstream activation of 
signaling pathway including NF-κB [159].  However, it is still unclear whether the 
TRAF6 membrane localization is associated with its activation. My study showed that 
various receptor stimulations activate Src tyrosine kinase and Src then phosphorylates 
and activates TRAF6. Since IRAKs and TIFA promote TRAF6 oligomerization and 
activation [157,158], it is highly possible that Src-mediated TRAF6 phosphorylation may 
also regulate TRAF6 membrane recruitment and activation. Our recent findings also 
support this hypothesis that IGF-1 stimulation increases TRAF6 membrane localization 
[23], and I have also observed that IL-1 stimulation increases membrane localization of 
TRAF6 wild-type or TRAF6 phospho-mimetic mutant, but not TRAF6 Y473F mutant 
(unpublished observation). Further investigation is needed to explore this possibility.   
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 5-4. What is the in vivo impact of Src-mediated TRAF6 Y473 phosphorylation? 
        During my thesis study, I revealed the novel molecular mechanism of how TRAF6 
is activated under diverse physiological stimuli including IGF-1, IL-1, LPS, and RANKL. 
In this study, I showed that Src-mediated TRAF6 Y473 phosphorylation is critical to 
regulate the TRAF6 E3 ligase activity and its oncogenic potential. I further showed the 
clinical relevance of Src activation and TRAF6 Y473 phosphorylation. These findings 
highlight the importance of TRAF6 Y473 phosphorylation in regulation of TRAF6 
activation and TRAF6-mediated tumorigenesis. 
        To further elucidate the in vivo relevance of Src-mediated TRAF6 Y473 
phosphorylation in tumorigenesis, future studies include generating and examining 
TRAF6, TRAF6 Y473D, and TRAF6 Y473F transgenic mice models. In addition, given 
the relevance of TRAF6 in host immunity, bone metabolism, autoimmune disease, and 
neurodegenerative diseases, generating and examining those TRAF6 transgenic mouse 
models will give us valuable information to advance our current knowledge of TRAF6 in 
human diseases. 
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